glp 1 drugs and cancer The science around GLP-1 is suddenly getting a lot more interesting GLP-1 Medications for Weight Loss:
Description
(Lausanne) 12 , 678055 (2021)

In the 2022 SURMOUNT-1 study published in NEJM, three doses of tirzepatide were compared with placebo (1:1:1:1) to determine effects on percent weight change over the course of 72 weeks

Pharmacol Rep
Its convenience and efficacy make it a popular choice for those seeking significant results
Appetite Suppressants

The optimistic interpretation is that GLP-1 receptor agonists could be contributing to a biologically meaningful improvement in breast cancer outcomes through weight loss, insulin regulation, cardiovascular benefit, inflammatory modulation, or direct tumor-related effects
